share_log

Top 5 Health Care Stocks That May Plunge In March

Top 5 Health Care Stocks That May Plunge In March

三月份可能暴跌的五大醫療保健股
Benzinga ·  03/28 20:30

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

截至2024年3月28日，醫療保健行業的五隻股票可能會向將動量視爲交易決策關鍵標準的投資者發出真正的警告。

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

RSI 是一種動量指標，它比較股票在價格上漲的日子和價格下跌的日子的走勢。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數高於70時，資產通常被視爲超買。

Here's the latest list of major overbought players in this sector.

以下是該行業主要超買參與者的最新名單。

The Pennant Group, Inc. (NASDAQ:PNTG)

彭南特集團有限公司（納斯達克股票代碼：PNTG）

  • On Feb. 28, Pennant posted better-than-expected quarterly sales. "We are pleased with our strong finish to 2023 and continued momentum as we enter 2024," said Brent Guerisoli, Pennant's Chief Executive Officer. "By executing on our five key focus areas--leadership development, clinical excellence, employee engagement, margin improvement, and growth--we made steady gains throughout 2023 and solidly delivered on earnings expectations, even after increasing guidance during the year." The company's stock gained around 18% over the past month and has a 52-week high of $20.50 .
  • RSI Value: 90.15
  • PNTG Price Action: Shares of Pennant Group gained 1.7% to close at $19.84 on Wednesday.
  • 2月28日，彭南公佈的季度銷售額好於預期。彭南特首席執行官布倫特·蓋裏索利表示：“我們對2023年的強勁表現以及進入2024年的持續勢頭感到滿意。”“通過執行我們的五個關鍵重點領域——領導力發展、臨床卓越表現、員工敬業度、利潤率提高和增長——我們在2023年全年取得了穩步增長，儘管年內提高了預期。”該公司的股票在過去一個月中上漲了約18％，並且 52 周高點爲 20.50 美元 。
  • RSI 值：90.15
  • PNTG價格走勢：彭南特集團股價週三上漲1.7％，收於19.84美元。

Mesoblast Limited (NASDAQ:MESO)

Mesoblast Limited（納斯達克股票代碼：MESO）

  • On March 25, the FDA informed Mesoblast that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The company's stock gained around 54% over the past five days and has a 52-week high of $10.24.
  • RSI Value: 71.74
  • MESO Price Action: Shares of Mesoblast dipped 11.2% to close at $3.49 on Wednesday.
  • 3月25日，美國食品藥品管理局告知Mesoblast，經過進一步考慮，其3期研究 MSB-GVHD001 的現有臨床數據似乎足以支持針對類固醇難治性急性移植物抗宿主病（sr-AGVHD）兒科患者的remestemcel-L的擬議生物製劑許可申請（BLA）。該公司的股票在過去五天中上漲了約54％， 創下 52 周新高 爲10.24美元。
  • RSI 值：71.74
  • MESO價格走勢：週三，Mesoblast的股價下跌11.2％，收於3.49美元。

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

ARS 製藥公司（納斯達克股票代碼：SPRY）

  • On March 21, ARS Pharmaceuticals reported a narrower-than-expected fourth-quarter loss. The company's stock gained around 13% over the past five days and has a 52-week high of $10.20.
  • RSI Value: 70.11
  • SPRY Price Action: Shares of ARS Pharmaceuticals fell 0.4% to close at $9.96 on Wednesday.
  • 3月21日，ARS製藥公司公佈的第四季度虧損低於預期。該公司的股票在過去五天中上漲了約13％，並且 52 周高點 爲10.20美元。
  • 相對強弱指數值：70.11
  • SPRY價格走勢：週三，ARS製藥公司股價下跌0.4％，收於9.96美元。

Neuronetics, Inc. (NASDAQ:STIM)

Neuronetics, Inc.（納斯達克股票代碼：STIM）

  • On March 25, NeuroStar Advanced Therapy received the FDA clearance as first-line add-on treatment for adolescents with depression. The company's stock jumped around 62% over the past month and has a 52-week high is $4.99.
  • RSI Value: 72.16
  • STIM Price Action: Shares of Neuronetics gained 0.8% to close at $4.80 on Wednesday.
  • 3月25日，NeuroStar高級療法作爲抑鬱症青少年的一線附加療法獲得了美國食品藥品管理局的批准。該公司的股票在過去一個月中上漲了約62％，創52周高點爲4.99美元。
  • RSI 值：72.16
  • STIM價格走勢：週三，Neuronetics的股價上漲0.8％，收於4.80美元。

Inozyme Pharma, Inc. (NASDAQ:INZY)

Inozyme Pharma, Inc.（納斯達克股票代碼：INZY）

  • On March 26, Inozyme Pharma announced that it will discuss topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency, and from all cohorts of its ongoing Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency. The company's stock jumped around 22% over the past five days and has a 52-week high of $7.56.
  • RSI Value: 71.56
  • INZY Price Action: Shares of Inozyme Pharma climbed 9% to close at $7.39 on Wednesday.
  • 3月26日，Inozyme Pharma宣佈，它將討論其正在進行的針對患有 ABCC6 的成年人的 INZ-701 1/2 期試驗以及正在進行的 ENPP1 缺乏成人 INZ-701 的 1/2 期試驗的主要數據。該公司的股票在過去五天中上漲了約22％， 創下 52 周新高 7.56 美元。
  • RSI 值：71.56
  • INZY價格走勢：週三，Inozyme Pharma的股價上漲了9％，收於7.39美元。

Read More: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday

閱讀更多： 進入週四，RH、Walgreens和3只股票值得關注

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論